Home / 3D Bioprinting / Keith Murphy to Step Down, Taylor J. Crouch Is the New CEO at Organovo

Keith Murphy to Step Down, Taylor J. Crouch Is the New CEO at Organovo

Keith Murphy will be stepping down as Chief Executive Officer of Organovo, one of the first pioneering companies in the blooming field of 3D bioprinting. Taylor J. Crouch, previously CEO of eStudySite, a leading investigative clinical research company, has been appointed by the Board to succeed Mr. Murphy, who will remain chairman of the board, and will serve as an advisor to the Company to ensure a seamless transition and offer his counsel and expertise.

“On behalf of the board, I want to thank Keith for his many contributions to Organovo and the groundbreaking innovations he helped pioneer.  Keith saw the value in 3D bioprinting technology before the market existed, and had the vision to take it from its earliest stages in academic labs, and develop it into a global business with a robust commercial platform and strong IP portfolio.  We support Keith’s decision to step down and agree this is the opportune time to bring Taylor on to lead Organovo in its next phase of commercial growth.  We also appreciate his willingness to continue to serve the Company.” Lead director, Kirk Malloy, Ph.D.

Mr. Crouch has over 25 years of experience building and leading technology, expertise and product-based companies in the life sciences and biotech industries.  For more than seven years, he has managed and served as an operational investor in a group of leading clinical research site companies.  Specifically, Mr. Crouch served as Chief Executive Officer at eStudySite, a position he held from January 2009 to June 2016; as Executive Chairman of Meridien Research from December 2013 to September 2016; and as a Director of the National Research Institute from September 2011 through July 2016.  He was instrumental in building these three sister companies, and helping them to achieve significant and profitable growth and to become recognized leaders in their respective fields of infectious disease, CNS disorders and metabolic disease.

“I am excited and honored to succeed Keith as Organovo’s CEO. Keith is an exceptional leader who built Organovo into the strong global company it is today.  I look forward to working with the seasoned management team and all my talented new colleagues to further advance 3D human tissue bioprinting technology, advance solutions that benefit patients and drive the commercialization and scale of our business.” Taylor J. Crouch, Organovo CEO.

Prior to this, Mr. Crouch served as Senior Vice President of Operations/President International at Ligand Pharmaceuticals from 2005 to 2007, with responsibilities for new business development, technical operations, international sales and clinical research.  Prior to Ligand, he was President and Chief Operating Officer of Discovery Partners International (NASDAQ: formerly DPII – a large drug discovery services and technology provider).  Earlier in his career, he was Chief Executive Officer of Variagenics (NASDAQ: formerly VGNX – a leading pharmacogenomics company), Senior Vice President of Marketing and Sales at Parexel – a global CRO, and he also held international management positions in new product development and commercialization at Pfizer and Schering Plough.  Mr. Crouch holds a BSE in chemical engineering, cum laude, from Princeton University and an MBA in international marketing and finance from the University of Chicago.

“I am extremely proud of the progress we have made in the last ten years achieving our vision for Organovo.  Our 3D bioprinted human tissues are a disruptive and game-changing technology.  Founding Organovo and guiding us to our leadership position in 3D bioprinting has been a privilege, and I am extremely grateful to my Organovo colleagues who assisted in building this success, as well as all of our partners and customers. I am a true believer in our existing tissue research services, the potential of our therapeutic liver tissue, and the future opportunities enabled by our platform technology.  The time is right to bring in a CEO with the relevant commercial experience to lead the company into its next stage.  I have great confidence in Organovo’s continued growth and success, and I look forward to working with the board and Taylor over the coming months to ensure that this transition is seamless for all of our stakeholders.” Keith Murphy, former Organovo CEO.

Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications.  The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners. Organovo’s 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost.  The Company’s ExVive Human Liver and Kidney Tissues are used in toxicology and other preclinical drug testing.  The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications.  In addition to numerous scientific publications, the Company’s technology has been featured in The Wall Street Journal, Time Magazine, The Economist, Forbes, and numerous other media outlets.  Organovo is changing the shape of life science research and transforming medical care.

“Taylor is uniquely positioned to lead our growing company into its next phase given his significant commercial and operations experience.  We are confident that Taylor’s extensive skills and expertise in the biotechnology and life sciences industries align with Organovo’s strategy to capitalize fully on its growth opportunities.  The board looks forward to working with Taylor and the management team to execute against our strategy and continuing to create meaningful value for stockholders. Lead director, Kirk Malloy, Ph.D.

About 3D Printing Media Network

Check Also

Safilo and Materialise Bring 3D Printed OXYDO Eyewear Collection to Market

The forward-looking made in Italy brand OXYDO goes eclectic, with the disruptive designs of the …

Leave a Reply

Your email address will not be published. Required fields are marked *